A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents
- Jan Philipp Bewersdorf
- , Rory M. Shallis
- , Elad Sharon
- , Silvia Park
- , Rahul Ramaswamy
- , Caroline E. Roe
- , Jonathan M. Irish
- , Anne Caldwell
- , Wei Wei
- , Abdulraheem Yacoub
- , Yazan F. Madanat
- , Joshua F. Zeidner
- , Jessica K. Altman
- , Olatoyosi Odenike
- , Swaroopa Yerrabothala
- , Tibor Kovacsovics
- , Nikolai A. Podoltsev
- , Stephanie Halene
- , Richard F. Little
- , Richard Piekarz
- Yale University
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- Vanderbilt University
- The University of Kansas Cancer Center
- University of Texas Southwestern Medical Center
- University of North Carolina at Chapel Hill
- Northwestern University
- The University of Chicago
- Dartmouth College
- University of Utah
Research output: Contribution to journal › Article › peer-review
17
Scopus
citations